Sugi Predict

Sugi Predict / Compounds / SCHEMBL2748441

SCHEMBL2748441

SCHEMBL2748441

COc1ccc(NC(=O)OC(C)(C)C)cn1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.58
▸ MEN1 O00255 5/20 0.58
▸ MAPT P10636 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ RAB9A P51151 6/20 0.57
▸ NPC1 O15118 5/20 0.57
▸ LMNA P02545 4/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HTT P42858 1/20 0.57
▸ PABPC1 P11940 4/20 0.56
▸ POLB P06746 2/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.50
▸ NAMPT P43490 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764668 1.00 KMT2A (0.58) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL31129249 0.85 KMT2A (0.67) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL10404298 0.85 KMT2A (0.67) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL19255115 0.85 KMT2A (0.49) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL5801478 0.84 NAMPT (0.50) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL29372463 0.83 NAMPT (0.51) NAMPT
SCHEMBL4910310 0.83 NAMPT (0.51) NAMPT
SCHEMBL25890386 0.82 ALDH1A1 (0.47) KMT2AMEN1MAPTKDM4ERAB9A
SCHEMBL6609814 0.81 NAMPT (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2NAMPT
SCHEMBL376258 0.81 NAMPT (0.56) NPSR1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116648453-A 5-and 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase 活力疗法公司 2023-08-25 — — CN disclosed
US-20230227483-A1 PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS GLENMARK SPECIALITY S.A. (CH) 2023-07-20 — — US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 — — US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 — — US disclosed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 — — CN disclosed
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2020-09-17 — — US disclosed
CN-111315723-A Extramembranous nucleotide pyrophosphatase-phosphodiesterase 1(ENPP-1) inhibitor and application thereof 艾伯维公司 2020-06-19 — — CN disclosed
EP-2776436-B1 NEW COMPOUNDS ASTEX THERAPEUTICS LTD (GB) 2019-03-13 — — EP disclosed
US-9757364-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2017-09-12 — — US disclosed
US-9757364-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LTD (GB) 2017-09-12 — — US disclosed
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. 2011-05-19 — — US disclosed
WO-2009151598-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2009-12-17 — — WO disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed
WO-2005040168-A1 AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-05-06 — — WO disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 — — WO disclosed
US-6380230-B1 FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS SANOFI-SYNTHELABO (FR) 2002-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KMT2A 3644/4885MEN1 261/4885MAPT 2653/4885
US-20110118230-A1 DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B KMT2A 2123/4885MEN1 945/4885MAPT 4241/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KMT2A 3644/4885MEN1 261/4885MAPT 2653/4885
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 KMT2A 3342/4885MEN1 3315/4885MAPT 4852/4885
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX KMT2A 3083/4885MEN1 3817/4885MAPT 1805/4885
US-20230227483-A1 PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS MAP4K1, MAP3K4, MAP4K2 KMT2A 2987/4885MEN1 2549/4885MAPT 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.